Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

New England Journal of Medicine

Volumn 348, Issue 22, 2003, Pages 2186-2195

  Lazzarin, Adriano ^a   Clotet, Bonaventura ^b   Cooper, David ^c   Reynes, Jacques ^d   Arastéh, Keikawus ^e   Nelson, Mark ^f   Katlama, Christine ^g   Stellbrink, Hans Jürgen ^h   Delfraissy, Jean François ⁱ   Lange, Joep ^j   Huson, Les ^k   DeMasi, Ralph ^l   Wat, Cynthia ^k   Delehanty, John ^l   Drobnes, Claude ^l   Salgo, Miklos ^m  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

^e Vivantes Auguste Viktoria Klinikum   (Germany)

^f CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁱ BICÊTRE HOSPITAL   (France)

^j UNIVERSITY OF AMSTERDAM   (Netherlands)

^k ROCHE PRODUCTS LTD   (United Kingdom)

^l Trimeris Pharmaceuticals   (United States)

^m HOFFMANN LA ROCHE INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; AGED; ARTICLE; ASTHENIA; BACTERIAL PNEUMONIA; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEPRESSION; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA; ERYTHEMA; FATIGUE; FEMALE; FEVER; FOLLOW UP; GENOTYPE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE; INSOMNIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NAUSEA; PAIN ASSESSMENT; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; REGRESSION ANALYSIS; SEPSIS; SKIN CYST; SKIN INDURATION; SKIN NODULE; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS RESISTANCE; VOMITING;

ADULT; ANTI-HIV AGENTS; AUSTRALIA; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; PATIENT COMPLIANCE; PEPTIDE FRAGMENTS; RNA, VIRAL;

EID: 0037849954     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa035211     Document Type: Article

References (21)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26.
3. Deeks SG. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clin Infect Dis 2000;30:Suppl 2:S177-S184.
4. Rousseau MN, Vergne L, Montes B, et al. Patterns of resistance mutations to anti-retroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;26:36-43. [Erratum, J Acquir Immune Defic Syndr 2001;26:395.]
5. Race E, Dam E, Obry V, Paulous S, Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 1999;13:2061-8.
6. Van Vaerenbergh K, Van Laethem K, Albert J, et al. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 2000;44:2109-17.
7. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993;9:1051-3.
8. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998;4:1302-7.
9. Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics, and anti-viral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002;18:685-93. [Erratum, AIDS Res Hum Retroviruses 2003;19:83.]
10. Lalezari JP, DeJesus E, Northfelt DW, et al. A controlled phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir, and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antiviral Ther (in press).
11. Lalezari JP, Eron JJ, Carlson M, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003;17:691-8.
12. Drobnes C, Fang L, Nelson E, et al. Tolerability of enfuvirtide (T-20) during chronic therapy in phase II trials. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., September 27-30, 2002. Washington, D.C.: American Society for Microbiology, 2002:262. abstract.
13. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85.
14. EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001;15:309-20.
15. Hammer SM, Vaida F, Bennett KK, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002;288:169-80.
16. Katlama C, Dominguez S, Duvivier C, et al. Long term benefit of treatment interruption in salvage therapy (GIGHAART ANRS 097). In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10-14, 2003: 81. abstract.
17. Lalezari J, Henry K, O'Hearn M, et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone: week 24 response among categories of treatment experience and baseline (BL) HIV antiretroviral (ARV) resistance. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., September 27-30, 2002. Washington, D.C.: American Society for Microbiology, 2002:266. abstract.
18. Lange J, Lazzarin A, Clotet B, et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone: week 24 response among categories of baseline (BL) demographics, treatment experience, and HIV antiretroviral (ARV) resistance. In: Program and abstracts of the Sixth International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, November 17-21, 2002:17-8. abstract.
19. Grossman H, Frechette G, Reyes F. Mega-HAART: complex protective regimens for HAART failure. In: Program and abstracts of the Second International Workshop on Salvage Therapy for HIV Infection, Toronto, May 19-21, 1999:246. abstract.
20. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998;72:986-93.
21. Greenberg ML, Melby T, Sista P, et al. Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 through 24 weeks. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10-14, 2003:108. abstract.